<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489850</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#17-001741</org_study_id>
    <nct_id>NCT03489850</nct_id>
  </id_info>
  <brief_title>Ibudilast and Withdrawal-Related Dysphoria</brief_title>
  <official_title>Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol use disorder (AUD) is a prevalent and disabling psychiatric disorder with few, and&#xD;
      only moderately efficacious, treatment options. Consequently, the identification of novel&#xD;
      treatment targets and the development of rigorous laboratory paradigms to screen and optimize&#xD;
      novel therapeutics represents a research priority. Ibudilast (IBUD) is a neuroimmune&#xD;
      modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory&#xD;
      factor. Recently in an AUD sample, IBUD was shown to decrease reactivity to a psychological&#xD;
      stressor. Furthermore, IBUD was effective in blunting alcohol reward among participants with&#xD;
      greater depressive symptoms, a hallmark symptom of protracted withdrawal. Recently,&#xD;
      preclinical research in opiates has demonstrated that drug withdrawal is necessary for&#xD;
      microglia activation and neuroinflammation in reward networks, suggesting that IBUD may be&#xD;
      most effective among patients who experience withdrawal-related dysphoria. Therefore, this&#xD;
      proposed study aims to examine withdrawal-related dysphoria as a moderator of IBUD efficacy&#xD;
      in the natural environment measured using Daily Diary Assessment (DDA) approaches. To&#xD;
      accomplish this aim, participants meeting criteria for AUD and balanced on the presence of&#xD;
      withdrawal-related dysphoria will be enrolled in a double-blinded IBUD trial including&#xD;
      consisting of two weeks randomized to medication and DDA assessment. The proposed research&#xD;
      aims are:&#xD;
&#xD;
      Aim 1: Test whether IBUD reduces basal negative affect in abstinence, and blunts&#xD;
      alcohol-related negative reinforcement. It is hypothesized that IBUD will reduce basal levels&#xD;
      of negative affect during alcohol abstinence, and in so doing will interfere with&#xD;
      alcohol-induced blunting of negative affectivity as captured during naturalistic drinking&#xD;
      episodes.&#xD;
&#xD;
      Aim 2: Test whether IBUD attenuates neural alcohol cue-reactivity. It is hypothesized that&#xD;
      IBUD will reduce BOLD activation to alcohol cues in mesocorticolimbic reward circuitry.&#xD;
&#xD;
      Aim 3: Test whether withdrawal-related dysphoria moderates the effects of IBUD. It is&#xD;
      hypothesized that IBUD will alleviate basal negative affect, interfere with alcohol-induced&#xD;
      negative reinforcement and attenuate BOLD activation to alcohol cues only among participants&#xD;
      who experience dysphoria in withdrawal.&#xD;
&#xD;
      Aim 4: Test whether neural activation to alcohol cues is predictive of drinking outcomes. It&#xD;
      is hypothesized that individuals with higher mesocorticolimbic activation to alcohol cues&#xD;
      will report more drinking in the week following the neuroimaging session.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Affect</measure>
    <time_frame>Assessed through daily prompts throughout the 2-week study period.</time_frame>
    <description>Negative affect as measured by self-reported ratings of &quot;Downhearted&quot;, &quot;Discouraged&quot;, &quot;Uneasy&quot;, and &quot;Anxious&quot;. Each item was rated on a scale from 0 (not at all) to 4 (extremely). The 4 items were summed for the total negative affect score for each day, ranging from 0 - 16. Higher scores indicate more negative mood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heavy Drinking</measure>
    <time_frame>14 days</time_frame>
    <description>Medication effects on number of heavy drinking days. Heavy drinking is defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as ≥5 drinks/day for men and ≥4 drinks/day for women. Values indicate estimated probability of a heavy drinking day across time for each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drinking</measure>
    <time_frame>14 days</time_frame>
    <description>Medication effects on number of days where any drinking was reported. . Values indicate estimated probability of a drinking day across time for each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventral Striatum Activation</measure>
    <time_frame>Day 8</time_frame>
    <description>Medication effect on alcohol cue-induced ventral striatal activation. Participants completed an fMRI alcohol cue-reactivity paradigm where they viewed pictures of alcoholic beverages, non-alcoholic beverages, blurred images, and a plus sign. The mean percent signal change between the ALC and BEV blocks was extracted from an a priori defined region of interest: bilateral ventral striatum (VS), 6 mm-radius sphere centered at ±12 6 9 in MNI space.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Ibudilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg BID Days 1-2 50mg BID Days 3-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched to active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibudilast</intervention_name>
    <description>Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.</description>
    <arm_group_label>Ibudilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is matched to ibudilast active medication.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 21 and 45&#xD;
&#xD;
          2. Meet DSM-5 criteria for current Moderate-to-Severe AUD&#xD;
&#xD;
          3. Current Heavy Drinking (&gt; 14 drinks per week for men; &gt; 7 drinks per week for women),&#xD;
             as indicated by self-reported drinking for the 30 days prior to screening&#xD;
&#xD;
          4. Have reliable internet access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently receiving or seeking treatment for AUD*&#xD;
&#xD;
          2. Past year DSM-5 diagnosis of any substance use disorder other than alcohol or nicotine&#xD;
&#xD;
          3. A lifetime diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder&#xD;
&#xD;
          4. Current use of drugs, other than marijuana, verified by a urine toxicology screen*&#xD;
&#xD;
          5. Pregnant, nursing, or refusal to use reliable birth control (if female)*&#xD;
&#xD;
          6. A medical condition that may interfere with safe participation (e.g., unstable&#xD;
             cardiac, renal, or liver disease, uncontrolled hypertension, diabetes, or AST, ALT, or&#xD;
             GGT ≥ 3 times upper normal limit)&#xD;
&#xD;
          7. Self-reported recent (i.e. past 30 day) use of medications that are contraindicated&#xD;
             with ibudilast*&#xD;
&#xD;
          8. Non-removable ferromagnetic objects in body&#xD;
&#xD;
          9. Claustrophobia&#xD;
&#xD;
         10. Serious head injury or prolonged period of unconsciousness (&gt;30 minutes)&#xD;
&#xD;
               -  Participants who meet these criteria at any point during the course of the study&#xD;
                  (i.e. after randomization) will be withdrawn from the study for safety purposes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lara A Ray, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ray LA, Bujarski S, Shoptaw S, Roche DJ, Heinzerling K, Miotto K. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. Neuropsychopharmacology. 2017 Aug;42(9):1776-1788. doi: 10.1038/npp.2017.10. Epub 2017 Jan 16.</citation>
    <PMID>28091532</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <results_first_submitted>April 9, 2021</results_first_submitted>
  <results_first_submitted_qc>October 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2021</results_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Lara Ray, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibudilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03489850/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03489850/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at an outpatient research clinic in a medical center. Participants were recruited through social media and mass transit advertisements. Initial screening was conducted through telephone interview, with eligible participants invited for an in-person assessment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibudilast</title>
          <description>20mg BID Days 1-2 50mg BID Days 3-14&#xD;
Ibudilast: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched to active&#xD;
Placebo: Placebo is matched to ibudilast active medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibudilast</title>
          <description>20mg BID Days 1-2 50mg BID Days 3-14&#xD;
Ibudilast: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched to active&#xD;
Placebo: Placebo is matched to ibudilast active medication.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.46" spread="9.24"/>
                    <measurement group_id="B2" value="31.07" spread="7.81"/>
                    <measurement group_id="B3" value="32.63" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.25" spread="2.64"/>
                    <measurement group_id="B2" value="15.21" spread="1.75"/>
                    <measurement group_id="B3" value="15.23" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Withdrawal Related Dysphoria</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use Disorder Symptom Count</title>
          <units>symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.29" spread="2.37"/>
                    <measurement group_id="B2" value="4.86" spread="2.27"/>
                    <measurement group_id="B3" value="5.06" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use Disorder Identification Test Total Score</title>
          <description>The AUDIT has 10 questions and the possible responses to each question are scored 0, 1, 2, 3 or 4, with the exception of questions 9 and 10 which have possible responses of 0, 2 and 4. The range of possible scores is from 0 to 40 where 0 indicates an abstainer who has never had any problems from alcohol. A score of 1 to 7 suggests low-risk consumption according to World Health Organization (WHO) guidelines. Scores from 8 to 14 suggest hazardous or harmful alcohol consumption and a score of 15 or more indicates the likelihood of alcohol dependence (moderate-severe alcohol use disorder).</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.38" spread="5.90"/>
                    <measurement group_id="B2" value="16.71" spread="6.42"/>
                    <measurement group_id="B3" value="16.56" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Dependence Scale Total Score</title>
          <description>Total scores can range from 0-47. A score of 0 indicates no symptoms. Scores from 1-13 indicate low level of dependence. Scores from 14-21 indicate intermediate levels of dependence. Scores from 22-30 indicate a substantial level of dependence. Scores above 30 indicate a severe level of dependence.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.00" spread="6.10"/>
                    <measurement group_id="B2" value="12.07" spread="7.01"/>
                    <measurement group_id="B3" value="12.50" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Penn Alcohol Craving Scale Total Score</title>
          <description>The PACS is a five-item, self-report measure that includes questions about the frequency, intensity, and duration of craving, the ability to resist drinking, and asks for an overall rating of craving for alcohol for the previous week. Scores can range from 0-30. A score of 0 indicates no craving for alcohol. Higher scores indicate higher craving for alcohol.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.79" spread="5.14"/>
                    <measurement group_id="B2" value="12.11" spread="7.04"/>
                    <measurement group_id="B3" value="12.43" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obsessive Compulsive Drinking Scale Total Score</title>
          <description>The Obsessive Compulsive Drinking Scale (OCDS) is a 14-item self-rating instrument that provides a total score that measures some cognitive aspects of alcohol craving. The total score range is from 0-40, with higher scores indicating greater severity of AUD. An OCDS total score of 7 and above discriminates between social drinkers and alcohol dependent drinkers, with a sensitivity of 93% and a specificity of 98%.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.54" spread="6.05"/>
                    <measurement group_id="B2" value="13.93" spread="8.07"/>
                    <measurement group_id="B3" value="14.21" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reasons for Heavy Drinking Questionnaire - Reinforcing</title>
          <description>The Reasons for Heavy Drinking Questionnaire is a brief assessment of motivations for heavy alcohol use. The Reinforcing sub-scale measures the tendency to drink for hedonic (positive reinforcement) and stress relief (negative reinforcement) motivations. Items 1-3 make up the reinforcement sub-scale. Scores range from 0-30. Higher scores indicate more endorsement of drinking motivation for reinforcement.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.29" spread="3.51"/>
                    <measurement group_id="B2" value="22.82" spread="4.88"/>
                    <measurement group_id="B3" value="23.04" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reasons for Heavy Drinking Questionnaire - Normalizing</title>
          <description>The Reasons for Heavy Drinking Questionnaire is a brief assessment of motivations for heavy alcohol use. The Normalizing sub-scale measures the tendency to drink to feel normal ore avoid withdrawal symptoms. Items 4-6 make up the reinforcement sub-scale. Scores range from 0-30. Higher scores indicate more endorsement of drinking motivation to feel normal.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.67" spread="7.10"/>
                    <measurement group_id="B2" value="8.29" spread="7.34"/>
                    <measurement group_id="B3" value="8.92" spread="7.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Drinks</title>
          <description>Total drinks measures the number of total standard alcoholic drinks consumed as reported on the 30-day Timeline Followback Interview (TLFB).</description>
          <units>drinks over prior 30 days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122.89" spread="64.58"/>
                    <measurement group_id="B2" value="114.9" spread="108.72"/>
                    <measurement group_id="B3" value="118.20" spread="90.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinking Days</title>
          <description>Drinking days measures the number of days an alcohol drink was consumed as reported on the 30-day Timeline Followback Interview (TLFB).</description>
          <units>number of days in the prior 30 days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.21" spread="6.87"/>
                    <measurement group_id="B2" value="20.25" spread="6.51"/>
                    <measurement group_id="B3" value="21.15" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinks Per Day</title>
          <description>Drinks per day measures the number of total standard alcoholic drinks consumed divided by 30 days (average number of drinks per day over 30 days) as reported on the 30-day Timeline Followback Interview (TLFB).</description>
          <units>average drinks over prior 30 days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.10" spread="2.15"/>
                    <measurement group_id="B2" value="3.81" spread="3.62"/>
                    <measurement group_id="B3" value="3.94" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinks Per Drinking Day</title>
          <units>drinks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.70" spread="2.58"/>
                    <measurement group_id="B2" value="5.34" spread="3.57"/>
                    <measurement group_id="B3" value="5.51" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heavy Drinking Days</title>
          <description>Heavy drinking days measures the number of days an individual met heavy drinking standards as reported on the 30-day Timeline Followback Interview (TLFB). Heavy drinking is defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as ≥5 drinks/day for men and ≥4 drinks/day for women.</description>
          <units>number of heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.79" spread="8.29"/>
                    <measurement group_id="B2" value="8.68" spread="8.04"/>
                    <measurement group_id="B3" value="9.65" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarette Smokers</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fagerstrom Test for Nicotine Dependence Score</title>
          <description>The Fagerstrom Test for Nicotine Dependence is summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.82" spread="2.82"/>
                    <measurement group_id="B2" value="1.07" spread="1.54"/>
                    <measurement group_id="B3" value="1.96" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cigarettes</title>
          <description>Total cigarettes measures the number of total cigarettes smoked as reported on the 30-day Timeline Followback Interview (TLFB).</description>
          <units>number of cigarettes smoked prior 30 day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.28" spread="79.85"/>
                    <measurement group_id="B2" value="133.07" spread="205.78"/>
                    <measurement group_id="B3" value="102.44" spread="197.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes Per Day</title>
          <units>cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.39" spread="8.70"/>
                    <measurement group_id="B2" value="5.06" spread="6.76"/>
                    <measurement group_id="B3" value="6.14" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>THC+ Urine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cannabis Days</title>
          <description>Cannabis days measures the number of days cannabis was used as reported on the 30-day Timeline Followback Interview (TLFB). Cannabis use was assessed by a binary yes or no for each day.</description>
          <units>number of days used in prior 30 days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.38" spread="9.99"/>
                    <measurement group_id="B2" value="8.15" spread="8.24"/>
                    <measurement group_id="B3" value="9.64" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beck Depression Inventory-II Total Score</title>
          <description>The Beck Depression Inventory-II is a 21-item self-administered survey which is scored on a scale of 0-3 in a list of four statements arranged in increasing severity about a particular symptom of depression. The scores are summed to give a total score. Scores of 0-13 indicate minimal symptoms of depression; scores of 14-19 indicate mild symptoms of depression; scores of 20-28 indicate moderate symptoms of depression; and scores of 29-63 indicate severe symptoms of depression;</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.42" spread="8.47"/>
                    <measurement group_id="B2" value="8.64" spread="7.2"/>
                    <measurement group_id="B3" value="10.38" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Negative Affect</title>
        <description>Negative affect as measured by self-reported ratings of &quot;Downhearted&quot;, &quot;Discouraged&quot;, &quot;Uneasy&quot;, and &quot;Anxious&quot;. Each item was rated on a scale from 0 (not at all) to 4 (extremely). The 4 items were summed for the total negative affect score for each day, ranging from 0 - 16. Higher scores indicate more negative mood.</description>
        <time_frame>Assessed through daily prompts throughout the 2-week study period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibudilast</title>
            <description>20mg BID Days 1-2 50mg BID Days 3-14&#xD;
Ibudilast: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched to active&#xD;
Placebo: Placebo is matched to ibudilast active medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Affect</title>
          <description>Negative affect as measured by self-reported ratings of &quot;Downhearted&quot;, &quot;Discouraged&quot;, &quot;Uneasy&quot;, and &quot;Anxious&quot;. Each item was rated on a scale from 0 (not at all) to 4 (extremely). The 4 items were summed for the total negative affect score for each day, ranging from 0 - 16. Higher scores indicate more negative mood.</description>
          <units>units</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="0.55"/>
                    <measurement group_id="O2" value="2.47" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.62</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Parameter Estimate</param_type>
            <param_value>0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heavy Drinking</title>
        <description>Medication effects on number of heavy drinking days. Heavy drinking is defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as ≥5 drinks/day for men and ≥4 drinks/day for women. Values indicate estimated probability of a heavy drinking day across time for each group.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibudilast</title>
            <description>20mg BID Days 1-2 50mg BID Days 3-14&#xD;
Ibudilast: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched to active&#xD;
Placebo: Placebo is matched to ibudilast active medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Heavy Drinking</title>
          <description>Medication effects on number of heavy drinking days. Heavy drinking is defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as ≥5 drinks/day for men and ≥4 drinks/day for women. Values indicate estimated probability of a heavy drinking day across time for each group.</description>
          <units>predicted probability in percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.16" lower_limit="17.12" upper_limit="32.94"/>
                    <measurement group_id="O2" value="36.80" lower_limit="28.43" upper_limit="46.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.30</ci_lower_limit>
            <ci_upper_limit>.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Drinking</title>
        <description>Medication effects on number of days where any drinking was reported. . Values indicate estimated probability of a drinking day across time for each group.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibudilast</title>
            <description>20mg BID Days 1-2 50mg BID Days 3-14&#xD;
Ibudilast: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched to active&#xD;
Placebo: Placebo is matched to ibudilast active medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Any Drinking</title>
          <description>Medication effects on number of days where any drinking was reported. . Values indicate estimated probability of a drinking day across time for each group.</description>
          <units>predicted probability in percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.25" lower_limit="47.62" upper_limit="69.92"/>
                    <measurement group_id="O2" value="63.63" lower_limit="54.65" upper_limit="71.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventral Striatum Activation</title>
        <description>Medication effect on alcohol cue-induced ventral striatal activation. Participants completed an fMRI alcohol cue-reactivity paradigm where they viewed pictures of alcoholic beverages, non-alcoholic beverages, blurred images, and a plus sign. The mean percent signal change between the ALC and BEV blocks was extracted from an a priori defined region of interest: bilateral ventral striatum (VS), 6 mm-radius sphere centered at ±12 6 9 in MNI space.</description>
        <time_frame>Day 8</time_frame>
        <population>Participants were excluded from neuroimaging analyses for the following reasons: participant missed mid-point study visit (n=1, placebo); participant could not be scanned due to COVID-19 safety restrictions (n=1, placebo); participant began scan but ended early due to claustrophobia (n=1, ibudilast); scanner issues prevented the collection of alcohol cue reactivity data (n=1, ibudilast); and participant was found to be not safe for MRI scanning on the day-of the study visit (n=1, ibudilast).</population>
        <group_list>
          <group group_id="O1">
            <title>Ibudilast</title>
            <description>20mg BID Days 1-2 50mg BID Days 3-14&#xD;
Ibudilast: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched to active&#xD;
Placebo: Placebo is matched to ibudilast active medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventral Striatum Activation</title>
          <description>Medication effect on alcohol cue-induced ventral striatal activation. Participants completed an fMRI alcohol cue-reactivity paradigm where they viewed pictures of alcoholic beverages, non-alcoholic beverages, blurred images, and a plus sign. The mean percent signal change between the ALC and BEV blocks was extracted from an a priori defined region of interest: bilateral ventral striatum (VS), 6 mm-radius sphere centered at ±12 6 9 in MNI space.</description>
          <population>Participants were excluded from neuroimaging analyses for the following reasons: participant missed mid-point study visit (n=1, placebo); participant could not be scanned due to COVID-19 safety restrictions (n=1, placebo); participant began scan but ended early due to claustrophobia (n=1, ibudilast); scanner issues prevented the collection of alcohol cue reactivity data (n=1, ibudilast); and participant was found to be not safe for MRI scanning on the day-of the study visit (n=1, ibudilast).</population>
          <units>percent signal change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.20"/>
                    <measurement group_id="O2" value="0.14" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>F</param_type>
            <param_value>7.36</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Side effects were elicited in open ended fashion and were reviewed by the study physicians (K.M and A.G.). Adverse events were coded using the MedDRA v22.0 coding dictionary. Treatment-emergent adverse events were defined as adverse events that started after the first dose of the study drug or worsened in intensity after the first dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibudilast</title>
          <description>20mg BID Days 1-2 50mg BID Days 3-14&#xD;
Ibudilast: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched to active&#xD;
Placebo: Placebo is matched to ibudilast active medication.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Frequent Bowel Movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Gut pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cold Sweat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Libido Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Grief Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold (Influenza)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Asthmatic Crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lara Ray</name_or_title>
      <organization>University of California Los Angeles</organization>
      <phone>310-794-5383</phone>
      <email>lararay@psych.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

